Inhibrx Biosciences will host a live webcast on September 8, 2026, to present primary endpoint results from the Phase 2 HexAgon study. The study evaluates the safety and efficacy of INBRX-106, a hexavalent OX40 agonist, combined with pembrolizumab versus pembrolizumab alone in first-line patients with PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. This data is important as it could demonstrate improved treatment options for this cancer type. The webcast will include a slide presentation and be available for 60 days after the event.
Alico, Inc. reports a Return on Invested Capital (ROIC) of 7.29%, slightly below its Weighted Average Cost of Capital (WACC) of 7.96%, resulting in an ROIC-to-WACC ratio of 0.92. This indicates the company is close to covering its capital costs but n...
DigitalOcean CEO Padmanabhan Srinivasan sold 20,483 shares of the company, generating $2.2 million from the transaction. This insider sale may indicate personal financial planning or a strategic move, but it does not necessarily reflect the company's...
The Toro Company reported strong third-quarter results with net sales up 8.4% to $1.23 billion and adjusted EPS of $1.33, beating estimates. Operational efficiency improved, pushing the adjusted operating margin to 13.9%, driven by productivity gains...
KNOT Offshore Partners LP reported strong Q2 2026 results, beating analyst expectations with an EPS of $0.10 versus an estimated loss of $0.03 and revenue of $96.78 million exceeding forecasts. The company maintained a high shuttle tanker fleet utili...
Alphabet CEO Sundar Pichai told employees that Waymo, the company's self-driving car unit, could start making a meaningful financial contribution as soon as 2027. This suggests that Alphabet's investment in autonomous driving technology may be closer...
